Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PROCEPT BioRobotics (PRCT) Research & Development (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Research & Development for 6 consecutive years, with $19.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 26.48% to $19.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $71.3 million, a 14.41% increase, with the full-year FY2025 number at $71.3 million, up 14.41% from a year prior.
  • Research & Development was $19.1 million for Q4 2025 at PROCEPT BioRobotics, up from $18.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $19.1 million in Q4 2025 to a low of $4.5 million in Q2 2021.
  • A 5-year average of $11.5 million and a median of $11.6 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 114.27% in 2023, then grew 0.75% in 2025.
  • PROCEPT BioRobotics' Research & Development stood at $5.1 million in 2021, then skyrocketed by 90.74% to $9.7 million in 2022, then soared by 49.72% to $14.5 million in 2023, then grew by 3.93% to $15.1 million in 2024, then increased by 26.48% to $19.1 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Research & Development are $19.1 million (Q4 2025), $18.2 million (Q3 2025), and $17.6 million (Q2 2025).